Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome

Fertil Steril. 2010 Nov;94(6):2437-40. doi: 10.1016/j.fertnstert.2010.02.032. Epub 2010 Apr 7.

Abstract

Antiphospholipid syndrome patients with recurrent miscarriage have an impairment in fibrinolysis demonstrated by prolonged clot lysis time (CLT) that cannot be attributed to differences in thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels. Patients with unexplained recurrent miscarriage have an impairment in fibrinolysis demonstrated by increased CLT, that can be at least partly explained by higher TAFI antigen levels.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abortion, Habitual / blood*
  • Abortion, Habitual / etiology
  • Adult
  • Antiphospholipid Syndrome / blood*
  • Antiphospholipid Syndrome / complications
  • Blood Coagulation / physiology
  • Blood Coagulation Tests
  • Carboxypeptidase B2 / analysis
  • Carboxypeptidase B2 / blood*
  • Case-Control Studies
  • Female
  • Fibrinolysis / physiology
  • Humans
  • Pregnancy
  • Time Factors

Substances

  • Carboxypeptidase B2